Ervebo, Merck's Ebola vaccine, reduced the fatality risk among patients who previously contracted the rare disease that kills 50% of those affected, according to new research.
In a review of more than 2,000 people with confirmed Ebola cases in the Democratic Republic of Congo, researchers found case fatality was 27% among Ervebo patients and 56% among unvaccinated patients. The findings were published Feb. 7 in The Lancet Infectious Diseases.
The study is the first to research the retrospective efficacy of the Ebola vaccine, the researchers said.